Systemic Therapy for Melanoma: ASCO Guideline.

Antineoplastic Combined Chemotherapy Protocols / therapeutic use Humans Imidazoles / administration & dosage Melanoma / drug therapy Meta-Analysis as Topic Oximes / administration & dosage Pyridones / administration & dosage Pyrimidinones / administration & dosage Randomized Controlled Trials as Topic Skin Neoplasms / drug therapy Systematic Reviews as Topic Uveal Neoplasms / drug therapy

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
20 11 2020
Historique:
pubmed: 2 4 2020
medline: 26 3 2021
entrez: 2 4 2020
Statut: ppublish

Résumé

To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma. In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D

Identifiants

DOI: 10.1200/JCO.20.00198 PMID: 32228358
pubmed: 32228358
doi: 10.1200/JCO.20.00198
doi:

Substances chimiques

Imidazoles 0
Oximes 0
Pyridones 0
Pyrimidinones 0
trametinib 33E86K87QN
dabrafenib QGP4HA4G1B

Types de publication

Journal Article Practice Guideline Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3947-3970

Commentaires et corrections

Type : ErratumIn

Auteurs

Rahul Seth (R)

State University of New York Upstate Medical University, Syracuse, NY.

Hans Messersmith (H)

American Society of Clinical Oncology, Alexandria, VA.

Varinder Kaur (V)

University of Virginia, Charlottesville, VA.

John M Kirkwood (JM)

University of Pittsburgh School of Medicine, Pittsburgh, PA.
University of Pittsburgh Medical Center, Hillman Cancer Institute, Pittsburgh, PA.

Ragini Kudchadkar (R)

Emory University, Atlanta, GA.

Jennifer Leigh McQuade (JL)

University of Texas MD Anderson Cancer Center, Houston, TX.

Anthony Provenzano (A)

Columbia Presbyterian Clinical Associates, Bronxville, NY.

Umang Swami (U)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

Jeffrey Weber (J)

Laura and Isaac Perlmutter Cancer Center at New York University, Langone Health, New York, NY.

Krishna C Alluri (KC)

St Luke's Mountain States Tumor Institute, Boise, ID.

Sanjiv Agarwala (S)

Lewis Katz School of Medicine at Temple University, Philadelphia, PA.

Paolo A Ascierto (PA)

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.

Michael B Atkins (MB)

Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

Nancy Davis (N)

Vanderbilt University Medical Center, Nashville, TN.

Marc S Ernstoff (MS)

Roswell Park Cancer Institute, Buffalo, NY.

Mark B Faries (MB)

The Angeles Clinic and Research Institute, Los Angeles, CA.
Cedars Sinai Medical Center, Los Angeles, CA.

Jason S Gold (JS)

Veterans Administration Boston Healthcare System, West Roxbury, MA.

Samantha Guild (S)

AIM at Melanoma Foundation, Frisco, TX.

David E Gyorki (DE)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Nikhil I Khushalani (NI)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Michael O Meyers (MO)

University of North Carolina School of Medicine, Chapel Hill, NC.

Caroline Robert (C)

Gustave Roussy Cancer Centre, Villejuif, France.
Paris-Saclay University, Villejuif, France.

Mario Santinami (M)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Amikar Sehdev (A)

Indiana University School of Medicine, Indianapolis, IN.

Vernon K Sondak (VK)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Gilliosa Spurrier (G)

Melanome France, Teilhet, France.

Katy K Tsai (KK)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

Alexander van Akkooi (A)

Netherlands Cancer Institute, Amsterdam, the Netherlands.

Pauline Funchain (P)

Cleveland Clinic, Cleveland, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méta-analyse comme sujet › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Composés chimiques organiques › Amines › Hydroxylamines › Oximes › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Pyridones › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Sciences de l'information › Sources d'information › Moyens de communication › Publications › Littérature de revue comme sujet › Revues systématiques comme sujet › Systemic Therapy for Melanoma: ASCO Guideline.
questionsmedicales.fr › Maladies de l'oeil › Maladies de l'uvée › Tumeurs de l'uvée › Systemic Therapy for Melanoma: ASCO Guideline.